Client Alert: DIR Report Demonstrates Downside of Drug Rebates for Consumers and Medicare Program

January 26, 2017 — Earlier this month, the U.S. Centers for Medicare & Medicaid Services (CMS) issued an analysis of direct and indirect remuneration (DIR) fees. The data presented in the report makes clear that despite the claims of pharmacy benefit managers (PBMs) to the contrary, DIR fees do not reduce the costs of drugs for [...]